- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01138345
Biomarkers in Blood Samples From Older Breast Cancer Survivors
The Effect of Chemotherapy on Aging in Older Women With Breast Cancer as Measured by Expression of p16INK4a
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment.
PURPOSE: This research study is studying biomarkers in blood samples from older women with stage I, stage II, or stage III breast cancer who have finished primary therapy or breast cancer survivors.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
OBJECTIVES:
Primary
- To measure and compare normalized p16^INK4a gene expression in women ≥ 65 years of age with stage I-III breast cancer who have completed primary therapy comprising surgery with or without radiotherapy followed by endocrine therapy (cohort 2) versus surgery with or without radiotherapy followed by chemotherapy and with or without endocrine therapy (cohort 3) .
- To measure and compare normalized p16^INK4a gene expression in women ≥ 65 years of age with stage I-III breast cancer who have completed primary therapy comprising surgery with or without radiotherapy (cohort 1) versus women treated in cohort 2.
- To compare normalized p16^INK4a gene expression between cohorts 1, 2, and 3 versus an age-matched contemporaneous control group of healthy volunteers accrued from a separate study (cohort 4).
Secondary
- To access functional status (ability to live independently at home and in the community), co-morbid medical conditions, cognition, psychological status, social functioning and support, medication review, nutritional status, and health-behavior status of these patients.
Tertiary (exploratory)
- To compare methodologies of p16 ^INK4a gene expression measurement in 50 patients in order to develop a batchable and analytically validated assay that eliminates the need for rapid sample processing.
- To explore any association between p16^INK4a expression and amount of vigorous physical activity, smoking habits, and/or weekly alcohol consumption.
- To explore any association between p16^INK4a expression and type of chemotherapy received, co-morbidities, concomitant medications, and/or tumor characteristics.
- To correlate p16^INK4a expression with scores from selected domains of the Geriatric Assessment (i.e., cognitive function, activities of daily living (ADL), and the instrumental ADL.
OUTLINE: Breast cancer survivors and healthy volunteers undergo blood collection for p16^INK4a gene expression analysis by Taqman RT-PCR.
Breast cancer survivors complete the Health Behavior and the Geriatric Assessment Questionnaires. They also complete a Timed Up and Go test to determine physical mobility.
Medical charts are reviewed to record information about diagnosis and treatment.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
DISEASE CHARACTERISTICS:
Histologically confirmed breast cancer
- Stage I-III disease
Breast cancer survivors meeting 1 of the following criteria:
- Prior surgery with or without (±) radiotherapy (RT) (cohort 1)
Prior surgery ± RT, followed by prior or concurrent hormonal (endocrine) therapy (cohort 2)
- Must have received or be on endocrine therapy for ≥ 3 months
- Prior surgery ± RT, followed by prior chemotherapy ± endocrine therapy (cohort 3)
- No recurrent disease
- No history of clonal bone marrow disorder (i.e., myelodysplastic or myeloproliferative disorder, acute or chronic leukemia)
PATIENT CHARACTERISTICS:
- Life expectancy > 12 months
- Absolute lymphocyte count > 500/μL
- No acute or active infection
- No other co-morbid illness that would impair ability to participate in the study
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 3 months since prior surgery with or without radiotherapy
- At least 3 months since prior chemotherapy (cohort 3)
- No concurrent radiotherapy, chemotherapy, or experimental therapy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
Treatment w/Surgery
Breast Cancer survivors treated with surgery with or without radiation.
|
blood samples will be analyzed for the expression of the p16 gene.
perform reverse transcriptase-polymerase chain reaction on all blood samples.
perform laboratory biomarker analysis on all blood samples
perform medical chart review for all subjects
each cohort will be given the same questionnaire
|
Treatment w/endocrine therapy
Breast Cancer survivors treated with surgery with or without radiation plus endocrine therapy.
|
blood samples will be analyzed for the expression of the p16 gene.
perform reverse transcriptase-polymerase chain reaction on all blood samples.
perform laboratory biomarker analysis on all blood samples
perform medical chart review for all subjects
each cohort will be given the same questionnaire
|
Treatment w/ chemotherapy
Breast Cancer survivors treated with surgery with or without radiation and chemotherapy with or without endocrine therapy.
|
blood samples will be analyzed for the expression of the p16 gene.
perform reverse transcriptase-polymerase chain reaction on all blood samples.
perform laboratory biomarker analysis on all blood samples
perform medical chart review for all subjects
each cohort will be given the same questionnaire
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
p16INK4a expression between cohort 2 vs cohort 3
Lasso di tempo: 2 years
|
2 years
|
p16INK4a expression between cohort 1 vs cohort 2
Lasso di tempo: 2 years
|
2 years
|
p16INK4a expression between cohorts 1, 2, and 3 vs cohort 4
Lasso di tempo: 2 years
|
2 years
|
Collaboratori e investigatori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- LCCC 0924
- P30CA016086 (Sovvenzione/contratto NIH degli Stati Uniti)
- CDR0000674103 (Altro identificatore: PDQ number)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro al seno
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University e altri collaboratoriCompletatoLa guida all'applicazione clinica di Conebeam Breast CTCina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsAttivo, non reclutanteEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaTaiwan, Stati Uniti, Olanda, Spagna, Corea, Repubblica di, Italia, Giappone, Canada, Singapore
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
Prove cliniche su gene expression analysis
-
Philips Consumer LifestyleCompletato
-
Vanderbilt University Medical Center4DMedicalCompletato
-
University of MiamiAttivo, non reclutante
-
Muğla Sıtkı Koçman UniversityCompletato
-
The University of Hong KongRitirato
-
TC Erciyes UniversityCompletatoSano | Disturbo dello spettro autistico | Autismo ad alto funzionamento
-
Fox Chase Cancer CenterNational Cancer Institute (NCI); Columbia University; Temple University; Herbert... e altri collaboratoriNon ancora reclutamento
-
Chiayi Christian HospitalSanofiSconosciuto
-
Histograft Co., Ltd.Moscow State University of Medicine and DentistryCompletatoPerdita di massa ossea | Perdita dei denti | Cisti ossee | Frattura dell'osso | Deformità ossea | Atrofia osseaFederazione Russa
-
Ruijin HospitalRenJi Hospital; West China Hospital; Shandong Provincial Hospital; Tianjin Medical... e altri collaboratoriReclutamentoLinfoma a cellule T perifericheCina